ACADIA Pharmaceuticals Inc
NASDAQ:ACAD

Watchlist Manager
ACADIA Pharmaceuticals Inc Logo
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
Watchlist
Price: 22.26 USD 26.48% Market Closed
Market Cap: 3.7B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+7%
Revenue
Forecast
+9%
Operating Income
Forecast
+10%
Net Income
Forecast
+11%

Wall Street
Price Targets

ACAD Price Targets Summary
ACADIA Pharmaceuticals Inc

Wall Street analysts forecast ACAD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ACAD is 24.69 USD with a low forecast of 11.11 USD and a high forecast of 38.85 USD.

ACAD Lowest Forecast
Wall Street Target
11.11 USD
50% Downside
ACAD Average Forecast
Wall Street Target
24.69 USD
11% Upside
ACAD Highest Forecast
Wall Street Target
38.85 USD
75% Upside
Lowest
Price Target
11.11 USD
50% Downside
Average
Price Target
24.69 USD
11% Upside
Highest
Price Target
38.85 USD
75% Upside
ACADIA Pharmaceuticals Inc Competitors:
Price Targets
2616
CStone Pharmaceuticals
4% Downside
EDIT
Editas Medicine Inc
153% Upside
V
VTGN
VistaGen Therapeutics Inc
430% Upside
OCX
OncoCyte Corp
65% Upside
2616
CStone Pharmaceuticals
4% Downside
EDIT
Editas Medicine Inc
153% Upside
V
VTGN
VistaGen Therapeutics Inc
430% Upside
OCX
OncoCyte Corp
65% Upside
B
2480
Beijing Luzhu Biotechnology Co Ltd
50% Upside
PHM
Pharma Mar SA
17% Upside
PAR
Paradigm Biopharmaceuticals Ltd
155% Upside
H
301207
Hualan Biological Bacterin Inc
19% Upside

Revenue
Forecast

Revenue Estimate
ACADIA Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for ACADIA Pharmaceuticals Inc's revenue is 65%. The projected CAGR for the next 3 years is 12%.

65%
Past Growth
12%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
ACADIA Pharmaceuticals Inc

The compound annual growth rate of ACADIA Pharmaceuticals Inc's operating income for the next 3 years is 45%.

N/A
Past Growth
45%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
ACADIA Pharmaceuticals Inc

The compound annual growth rate of ACADIA Pharmaceuticals Inc's net income for the next 3 years is 1%.

N/A
Past Growth
1%
Estimated Growth
Estimates Accuracy
-10%
Average Miss
What are analyst estimates?

See Also

Summary
ACAD intrinsic value, competitors valuation, and company profile.
DCF Valuation
ACAD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ACAD stock valuation using valuation multiples.
Wall Street Estimates
ACAD price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ACAD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ACAD's stock price target?
Price Target
24.69 USD

According to Wall Street analysts, the average 1-year price target for ACAD is 24.69 USD with a low forecast of 11.11 USD and a high forecast of 38.85 USD.

What is ACADIA Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
12%

For the last 8 years the compound annual growth rate for ACADIA Pharmaceuticals Inc's revenue is 65%. The projected CAGR for the next 3 years is 12%.

What is ACADIA Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
45%

The compound annual growth rate of ACADIA Pharmaceuticals Inc's operating income for the next 3 years is 45%.

What is ACADIA Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
1%

The compound annual growth rate of ACADIA Pharmaceuticals Inc's net income for the next 3 years is 1%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 255,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.